KDM1A and neoplasm: The potential success of such approaches is supported by the findings of Sheng et al. (2018) who showed that the genetic or pharmacological ablation of the histone demethylase LSD1 (HGNC: KDM1A) enhances tumor immunogenicity by stimulating HERV expression [90].